Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
What is Aprea Therapeutics's quote symbol?
What is the 52 week high and low for Aprea Therapeutics (NASDAQ: APRE)?
How much is Aprea Therapeutics stock worth today?
How much is Aprea Therapeutics's stock price per share?
What is Aprea Therapeutics's Market Cap?